Date of Report (Date of earliest event reported): March 2, 2021
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
of incorporation)
File Number)
(IRS Employer
Identification Number)
75 Hayden Avenue
Lexington, Massachusetts
(Address of registrant’s principal executive office)
 (Zip code)
(617) 621-8097
(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered
Common Stock, par value $0.0001 per shareDRNAThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 7.01    Regulation FD Disclosure
The Company from time to time presents and/or distributes to the investment community at various industry and other conferences and/or at other meetings slide presentations to provide updates and summaries of its business. The Company is posting to the “Investors & Media” portion of its website at http://investors.dicerna.com/ a copy of its current corporate slide presentation. These slides are attached to this Current Report on Form 8-K as Exhibit 99.1. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.
The information in Item 7.01 of this Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01    Financial Statements and Exhibits
(d) Exhibits
104Cover Page Interactive Data File (embedded within the Inline XBRL document).


Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

/s/ Douglas M. Fambrough, III
Douglas M. Fambrough, III, Ph.D.
Chief Executive Officer

Corporate Overview Discovery to Commercialization RNAi Platform March 2021

Forward-Looking Statements This presentation has been prepared by Dicerna Pharmaceuticals, Inc. (“we,” “us,” “our,” “Dicerna,” or the “Company”) and includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Examples of forward-looking statements include, among others, statements we make regarding: (i) the therapeutic and commercial potential of nedosiran, RG6346, belcesiran (formerly DCR-A1AT), DCR-AUD and the GalXC™ platform; (ii) expectations about our cash, cash equivalents and marketable securities; (iii) research and development plans and timelines, as well as regulatory pathways and plans, related to nedosiran, RG6346, belcesiran, DCR-AUD, GalXC and GalXC-Plus™; (iv) the potential of Dicerna’s technology and drug candidates in the Company’s research and development pipeline, including our pipeline expansion efforts and expectations; (v) the Company’s collaborations with Novo Nordisk A/S; Roche; Eli Lilly and Company; Alexion Pharmaceuticals, Inc.; Boehringer Ingelheim International GmbH; and Alnylam Pharmaceuticals, Inc.; and (vi) the Company’s strategy, business plans and focus. The process by which an early-stage investigational therapy such as nedosiran and an early-stage platform such as GalXC could potentially lead to an approved product is long and subject to significant risks. Applicable risks and uncertainties include, but are not limited to, those risks identified under the heading "Risk Factors" included in the Company’s most recent Form 10-K filing and in other subsequent filings with the Securities and Exchange Commission. These risks and uncertainties include, among others, the impact to, and potential for delays in, the current and future conduct of the business of the Company, its clinical programs and operations as a result of the COVID-19 pandemic; the cost, timing and results of preclinical studies and clinical trials and other development activities; the likelihood of Dicerna’s clinical programs being executed within timelines provided and reliance on the Company’s contract research organizations and predictability of timely enrollment of subjects and patients to advance Dicerna’s clinical trials; the potential for future data to alter initial, interim and preliminary results of clinical trials, including the multidose data from the PHYOX™3 trial of nedosiran; the unpredictability of the duration and results of the regulatory review of Investigational New Drug (IND) applications and Clinical Trial Applications that are necessary to continue to advance and progress the Company’s clinical programs and the regulatory review of submissions relevant to regulatory agencies for marketing approvals, including New Drug Applications (NDAs); market acceptance for approved products and innovative therapeutic treatments; competition; the possible impairment of, inability to obtain and costs of obtaining needed intellectual property rights; possible safety or efficacy concerns that could emerge as new data are generated in R&D; that the Company may not realize the intended benefits of its collaborations; general business, financial and accounting risks; and the risks and potential outcomes from litigation. Dicerna is providing this information as of this date and does not undertake any obligation to update or revise it, whether as a result of new information, future events or circumstances or otherwise. Additional information concerning Dicerna and its business may be available in press releases or other public announcements and public filings made after the date of this information. 2 Dicerna™, GalXC™, GalXC-Plus™ and PHYOX™ are trademarks of Dicerna Pharmaceuticals, Inc.

Dicerna was founded to specialize in RNAi Partner of Choice: Several large pharmas have chosen Dicerna for RNAi collaboration The RNAi Modality Has Come of Age RNAi Has Been Successful Where Traditional Modalities Have Not 3 Gene Targeting Across Multiple Tissue Types Approved Products in Multiple Disease Areas Simple & Convenient Dosing Regimens Multiple Committed Large Pharmas

RNAi Delivery Is Extending to Multiple Tissues Beyond the Liver The Future Is Bright 4 Alzheimer’s, Parkinson’s, frontotemporal dementia, Huntington’s, spinal cord injury, other rare diseases and more Immuno-oncology Diabetes, obesity, rare diseases and more Diseases of the lung, eye, kidney, etc. Myotonic dystrophy, other rare diseases Rare disease, HBV, cholesterol, NASH, cardiometabolic diseases, AUD and more Adipose Tumor-Associated Immune Cells Additional Tissues Muscle Central Nervous System Liver

Dicerna Is an Engine of Discovery and Development Core Clinical Pipeline Current pipeline yields multiple major milestones over next year+ • Nedosiran: A differentiated potential therapy for all primary hyperoxaluria (PH) types (PH1, PH2 and PH3) • RG6346: Potential best-in-class therapeutic with strong and durable HBsAg reduction for treatment of chronic hepatitis B virus (HBV) infection • Belcesiran: Targeting alpha-1 antitrypsin deficiency-associated liver disease (AATLD) • DCR-AUD: Targeting ALDH2 for alcohol use disorder (AUD) Proprietary and Collaboration Program Portfolios Provide for Consistent Funding Stream 5 Shots on Goal • 20+ discovery programs in multiple tissue types • 5 programs in IND-enabling studies • 1st partner compound already in clinic De-Risked Technology Platform • Supported by multiple clinical programs • Validated by multiple major pharma collaborations • Delivery to multiple tissues: liver, nervous system, muscle, adipose, tumor-associated immune cells and more Milestone-Rich 2021 Key data readouts, NDA filing, clinical entries and collaboration payments • $568.8M in cash, cash equivalents and marketable securities at 12/31/2020 • Expect little change between 2020 and 2021 year-end net cash positions, assuming no follow-on stock offering

With 20+ discovery-stage programs in multiple tissues Core and Collaborative Development-Stage Programs Ten Programs Have Entered Development, Many More Are in Discovery Stage 6 TARGET INDICATION COMPOUND (GENE TARGET) PRECLINICAL EARLY CLINICAL TRIALS REGISTRATION TRIALS DICERNA PRODUCT RIGHTS PARTNER Primary Hyperoxaluria 1, 2 & 3 100% global AAT Liver Disease 100% U.S. (Alnylam ex-U.S. opt-in) Chronic Hepatitis B U.S. opt-in Alcohol Use Disorder 100% global Cardiometabolic Opt-in to co-dev. and co-comm. Cardiometabolic Milestone/royalty Cardiometabolic Milestone/royalty Cardiometabolic Milestone/royalty Complement-mediated Milestone/royalty Complement-mediated Milestone/royalty Nedosiran (LDHA) Belcesiran (SERPINA1) DCR-AUD (ALDH2) LY3819469 (LPA) RG6346 (HBV) DCR-COMP1 (C3) DCR-COMP2 (CFB) LY3561774 (ANGPTL3) LY3849889 DCR-NOVO1 Anticipated Timing: IND filing for DCR-AUD expected mid-2021 IND filings for LY3819469 and LY3849889 are Lilly’s responsibility and are anticipated in Q2’21 and Q1’22, respectively. Dicerna intends to deliver IND-supporting packages to Alexion for DCR-COMP1 and DCR-COMP2 in Q4’21 and Q1’22, respectively; IND/CTA filings are the responsibility of Alexion and are at their discretion.

GalXC-Plus builds on GalXC’s favorable preclinical and clinical characteristics + additional remarkable flexibility for medicinal chemistry optimization and expansion into new therapeutic areas GalXC RNAi technology offers excellent pharmacological properties to de-risk development • Sequence-specificity to silence only the targeted gene in only the delivery tissues • Long duration of action – weeks to months – enables convenient dosing regimens • Off-target activity and side effects are generally not observed • Ability to address previously “undruggable” target classes Comprising new, proprietary technological advances that extend our RNAi silencing expertise beyond the liver to address new tissues and disease areas. De-Risked RNAi Technologies: & Delivery to Liver, Central Nervous System and Multiple Other Tissue Types Proprietary technology enabling subcutaneous delivery of GalNAc-mediated RNAi therapies that are designed to bind specifically to receptors on liver cells. Enables delivery to multiple tissues including CNS, muscle, adipose tissue, tumors and more GalNAc liver delivery 7 Including alternative nucleic acid structures Various ligands

Key Value Drivers • Core Clinical Programs ‒ Nedosiran for primary hyperoxaluria (PH) ‒ RG6346 for chronic hepatitis B virus (HBV) ‒ Belcesiran for alpha-1 antitrypsin deficiency-associated liver disease (AATLD) ‒ DCR-AUD for alcohol use disorder (AUD) • Collaborative Programs ‒ Roche and Novo opt-in programs • Extrahepatic Discovery Efforts • Commercial Infrastructure • Team and Balance Sheet 8

Nedosiran for the Treatment of Primary Hyperoxaluria (PH)

The Disease: Primary Hyperoxaluria A Family of Ultra-Rare, Life-Threatening Genetic Disorders Resulting in Renal Complications GO = glycolate oxidase LDHA = lactate dehydrogenase A CKD= chronic kidney disease ESRD= end-stage renal disease 10 Kidney function preservation Kidney stones Impacted by ESRD & systemic oxalosis Targeting GO blocks glyoxylate in PH1 only (lumasiran) Known Types of Primary Hyperoxaluria PH1 Genetic mutation AGXT PH2 Genetic mutation GRHPR PH3 Genetic mutation HOGA1 GO Glyoxylate Glyoxylate Glyoxylate Oxalate Oxalate Oxalate Calcium oxalate crystallization can lead to kidney stones, CKD, ESRD - dual liver-kidney transplant is only cure Nedosiran blocks final common pathway of oxalate production by silencing LDHA

The Opportunity: Nedosiran Is the Only RNAi Drug Candidate for All PH Types Planned Commercial Launch in 1H 2022 11 comprehensive treatment option for all patients with PH Education Estimated PH Diagnosis Rates PH1 PH2 PH3 Current Diagnosis Projections^ ~40% – 50% ~10% ~7% Diagnostic Testing Patient & Caregiver Support Dicerna estimates nedosiran global sales >$500M Expected U.S. Prevalence1,2 Prevalence based on PH mutant alleles found in the National Heart, Lung, and Blood Institute Exome Sequencing Project (NHLBI ESP) and calculated according to Hardy- Weinberg equilibrium for each PH type using the sum of all alternate PH1, PH2 or PH3 alleles (known, or known and scored as pathogenic) and all wild type alleles. 1. Hopp K, et al. J Am Soc Nephrol. 2015;26(10):2559-2570. 2. U.S. Census Bureau population on a date: February 20, 2020. United States Census Bureau website, 2020. ^ Sources: Dicerna internal estimates PH claims/registry analysis and scientific advisors. Analysts’ projections Similar numbers for major EU markets Dicerna is building commercial capabilities to market and sell nedosiran in the U.S. convenient once-monthly dosing with self-administration

The Data: Average Oxalate Levels Normalized After Nedosiran Treatment Results From Ongoing Multidose Open-Label PHYOX™3 Trial 12 *One participant was missing Uox value at Day 60; BSA = body surface area adjusted; Uox = urinary oxalate Nedosiran was generally well tolerated, and no serious safety concerns were identified in this ongoing study. For more information, including additional safety results from the PHYOX3 interim analysis, see Dicerna’s Oct. 22, 2020 presentation at ASN’s Kidney Week 2020. 24 -h r U ri na ry O xa la te C or re ct ed fo r BS A (m m ol /1 .7 3m 2 BS A /2 4 hr ) M ea n ± SE M Pre-treatment Baseline PHYOX3 Screening 60* 90 120 150 180 Visit (Day) 30 < 0.46 normal 1.7 1.4 1.1 0.8 0.5 0.2 ≥ 0.46 and < 0.60 near normal ≥ 0.69 (1.5x normal) 100% of Participants, Regardless of PH Subtype, Achieved Normal or Near-Normal Uox Excretion by Day 180 PH Type Patients Reaching Normalization PH1 (n=10) 100% PH2 (n=3) 67% PH1+PH2 (n=13) 92% 71% Reduction from baseline at day 180

The Plan: Building Dicerna’s Commercial Infrastructure Striving for Best-in-Class Service to the PH Community 13 Serving a rare disease community requires long-term comprehensive commitment and dedication Education Disease education for HCPs, payors and patients on all aspects of PH • Medical Science Liaison force in field and engaging therapeutic experts and HCPs • Educational resources for the PH community, e.g., UncoveringPH.com • Dicerna is committed to advancing the state of the science across PH disease Patient Support Patient and caregiver support across the treatment journey • Individualized engagement to help patients manage their PH • Facilitate therapy access with payors • Comprehensive treatment support PH Diagnostic Testing Diagnostic testing is a key resource for differential diagnosis • Company-supported renal rare disease diagnostic panel already deployed • Patients with PH1, PH2 and PH3 have already been identified • PH testing program can be leveraged globally Launch Infrastructure Preparation for planned product launch in 2022 • Compliance systems built • Financial and back-office infrastructure being assembled • Training curriculum in development • Recruiting sales leadership

RG6346 for the Treatment of Chronic Hepatitis B Virus (HBV) Infection

The Disease: Chronic HBV Is a Severe, Global Unmet Medical Need • Significant worldwide prevalence: ~292 million infected, >880,000 deaths per year • Current treatments are rarely effective in achieving functional cures • Collaborating with • Roche to conduct Phase 2 combination clinical studies with RG6346 and multiple additional mechanisms: ‒ Nucleos(t)ide (NUC), Interferon, TLR7 agonist, core inhibitor (CpAM) • Dicerna “opt-in” to co-fund development for enhanced U.S. economics and co- commercialization rights • Multi-billion $ opportunity 15 HBV “decoy” particles and filaments (HBV S Antigen) and infectious viral particles from patient blood Clinicaltrials.gov NCT04225715 Sources: Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. The Lancet Gastroenterology and Hepatology. Volume 3, Issue 6, June 2018, Pages 383-403. Hepatitis B Foundation. Facts and Figures. Available at: http://www.hepb.org/what-is-hepatitis-b/what-is-hepb/facts-and-figures/. Accessed on Jan. 8, 2021.

Mean HBsAg log10 IU/mL Change From Baseline The Data: Reductions in HBsAg Levels Ongoing One Year After Last Dose NUC-Suppressed Chronic HBV Participants (Group C) Given 4 Monthly Doses 16 • 1.8 log10 mean reduction (IU/ml) of hepatitis B surface antigen (HBsAg) (3 mg/kg and 6 mg/kg cohorts) • 2.7 log10 maximum reduction of HBsAg (participant in 3 mg/kg cohort) • 75% achieved ≥1.5 log10 reduction of HBsAg (9 of 12 participants) • 92% achieved ≥1.0 log10 reduction of HBsAg (11 of 12 participants) • 58% achieved HBsAg levels below 100 IU/ml (7 of 12 participants) • 1.40 log10 mean HBsAg reduction (IU/ml) at Day 448 in longest-observed cohort (1.5 mg/kg cohort, n=3) There were no serious adverse events (SAEs) reported for participants treated with RG6346 in this trial, and there were no dose-limiting toxicities or safety-related discontinuations (data presented at AASLD’s The Liver Meeting® Digital Experience™ 2020, Nov. 16, 2020). For more information, including additional safety results from the Phase 1 trial, see the poster and presentation from the AASLD conference. Four monthly injections RG6346 or placebo Phase 1 Data:

Belcesiran for the Treatment of Alpha-1 Antitrypsin (AAT) Deficiency-Associated Liver Disease (AATLD)

Belcesiran for AAT Deficiency-Associated Liver Disease (AATLD) Significant Opportunity In a Rare, Genetic Condition That Can Lead to Liver Disease • Z-allele of SERPINA1 gene produces abnormal AAT protein that may lead to chronic liver disease culminating in cirrhosis, liver failure, cancer. No available treatment other than liver transplant ‒ Lung disease may develop from lack of normal protein, which may be treated by protein replacement therapy • Approx. 120,000 individuals in Europe and 63,000 individuals in the U.S. carry the ZZ genotype1 ‒ Approx. 10% of individuals with ZZ genotype are diagnosed2 with AATLD. AATLD remains highly underdiagnosed3 • Belcesiran (formerly DCR-A1AT) Phase 2 expected to start in 1H 2021 for the treatment of AATLD • Phase 1 ongoing; initial data to be presented in mid-2021 • Dicerna driving global development through approval ‒ Alnylam can opt-in to ex-U.S. commercial rights post-pivotal data 18 1. Blanco et al. 2017; 2. Tanash & Piitulainen 2019; 3. Strnad et al., 2020; Narayanan & Mistry 2020 Janciauskiene et al. 2013: Acute Phase Proteins Loss of normal proteinToxic gain of function α1-Antitrypsin Deficiency Z mutation Glu342→Lys342 Polymerization of α1-antitrypsin Intracellular accumulation liver disease Plasma deficiency early-onset emphysema

DCR-AUD for the Treatment of Alcohol Use Disorder (AUD)

The Impact and Opportunity • AUD: A disorder characterized by the inability to stop or control alcohol use despite social, occupational or health consequences • ~95,000 deaths each year in U.S. due to alcohol-related causes A New Potential Therapeutic Approach to Treating AUD • DCR-AUD is designed to silence selectively ALDH2 in the liver ‒ ALDH2 encodes a key enzyme in alcohol metabolism ‒ Naturally occurring ALDH2 mutations dramatically reduce the risk of AUD in humans • Qualities of RNAi match the needs of AUD ‒ Monthly or longer duration with easy, subcutaneous dosing for improved compliance ‒ High gene target and liver specificity to reduce off-target effects ‒ High tolerability observed in programs to date • Phase 1 to provide go/no-go insights ‒ IND filing planned mid-2021; Phase 1 initiation in Q3 2021 ‒ Safety, tolerability, PK and PD study of single and multiple ascending doses of DCR-AUD in healthy volunteers ‒ Will assess drinking tolerance before and after administration • We believe DCR-AUD may potentially be a game-changer in the improvement of treatment outcomes for those with AUD Developing DCR-AUD for the Treatment of Alcohol Use Disorder (AUD) 20 NIAAA Alcohol Facts and Statistics, Oct 2020; 2018 National Survey on Drug Use and Health; https://www.cdc.gov/features/costsofdrinking/index.html; Grant et al., JAMA Psychiatry 2015; https://www.census.gov/quickfacts/fact/table/US/PST045219 A Significant Unmet Need for an Underdiagnosed Disorder Affecting Millions • Large opportunity exists for new therapies that are safe, effective, facilitate compliance and are complementary to widely used behavioral therapy Receiving Treatment (mostly behavioral therapy) AUD in U.S. Adults 10% <140,000 are offered medication for AUD 90% untreated 10% treated 14M Total <1.4M Total

Corporate Collaborations

Successfully Executing on High-Value Collaboration Strategy • Broad therapeutic areas including rare and common diseases: cardiovascular disease, NASH, cardiometabolic diseases, etc. • First collaborative program entered clinic Q4 2020 • Expect 2-3 clinical entries in 2021 • >20 discovery and preclinical programs Expect More Than $83 Million in Payments Received in 2021 22 $175M upfront $75M total annuals $50M equity$200M upfront $100M upfront $100M equity • 1 NASH Target • $5M option exercised $10M upfront $22M upfront $15M equity Nov. 2017 Oct. 2018 Oct. 2018 Oct. 2019 Nov. 2019 Dicerna retains opt-in rights • 4 complement- mediated targets • $20M option exercised • Up to 8 cardiometabolic targets, liver and non-liver • Neurodegeneration & pain targets • DRNA retains rights to certain neuro orphan indications • RG6346 (RO7445482) and multiple potential HBV-related targets • DRNA option to co- fund development and co-promote in U.S. • 30+ potential targets for liver-related CM diseases • 2 Novo programs: DRNA opt-in • DRNA retains rights to 2 new orphan programs (Novo retains opt-in rights) >$500 million in upfront and milestone payments received to date

Extrahepatic Platform

: Broad Opportunity in Tissues Beyond the Liver Future Pipeline and Collaborations to Include Delivery Beyond Liver 24 Dicerna TIDES Europe Presentation, Nov. 10, 2020 100% owned technology Up to 99% gene silencing in non-human primate models from a single dose Rare diseases and large-market neurodegeneration opportunities Up to 85% gene silencing in non-human primate models from a single subcutaneous dose Specific orphan indications in discovery Up to 85% gene silencing in non-human primate models from a single subcutaneous dose Orphan and large-market metabolic opportunities Optimization ongoing in additional tissues, including tumor-associated immune cells and more partnered with Neurodegeneration & Pain 100% owned technology Muscle Tissue Adipose Tissue

Management Team Leading Experts in RNAi Technology, Clinical, Regulatory and Commercial Operations 25 Douglas M. Fambrough, Ph.D. President and Chief Executive Officer Douglas Pagán Chief Financial Officer Rob Ciappenelli Chief Commercial Officer Shreeram Aradhye, M.D. EVP, Chief Medical Officer Bob D. Brown, Ph.D. EVP R&D, Chief Scientific Officer Jim Weissman EVP, Chief Operating Officer Ling Zeng, J.D. Chief Legal Officer & Secretary Jennifer Lockridge, Ph.D. SVP, Program Development James Powell SVP, Technical Operations Regina DeTore Paglia Chief Human Resources Officer • Dicerna founder • Sirna Therapeutics • Whitehead/Broad Institute • Ph.D., UC Berkeley • Joined Dicerna in 2012 • VP, BD of MannKind Corp • Pfizer, Pharmacia • Joined Dicerna in 2020 • CMO & Global Head Med. Affairs, Novartis Pharma • M.D., All India Institute of Medical Sciences • Joined Dicerna in 2020 • CFO, KSQ Therapeutics • CFO, Paratek • MBA, Columbia University • Joined Dicerna in 2019 • Global Head Commercial, Momenta • US Head Commercial Ops, Shire • MBA, Harvard University • Joined Dicerna in 2008 • VP, Research & Technology, Genta • Cofounder, Oasis Biosciences • Ph.D., UC Berkeley • Joined Dicerna in 2020 • Deputy Head Legal M&A, Novartis • VP, GC for Europe, Bausch • JD, Georgetown University • Joined Dicerna in 2016 • Sirna Therapeutics • Ribozyme Pharmaceuticals • Ph.D., Oregon Health Sciences • Joined Dicerna in 2017 • General Manager, Oligo manufacturing Agilent • Eyetech • Joined Dicerna in 2019 • SVP, HR, Paratek • SVP, HR, Myriant Corp • MA, Framingham State

Strong Balance Sheet Dicerna’s Business Model Has Potential to Fund Robust Pipeline Growth Expect balance sheet to remain strong due to product revenue, payments from existing collaborations, new collaborations, and asset monetization (does not include any proceeds from potential follow-on stock offerings) 26 & Clinical Programs

Target Milestones To Drive Momentum in 2021 Focused on Execution 27 • Nedosiran for PH (PH1, PH2, PH3)  Complete pivotal enrollment  Top-line PHYOX2 pivotal data mid-year 2021  PHYOX4 data in PH3 mid-year 2021  NDA submission Q3 2021  Prepare for 2022 target launch • RG6346 for HBV  Phase 2 study initiation Q1 2021 • Belcesiran for AATLD  Phase 2 initiation 1H 2021  Phase 1 data presentation in 2021 • DCR-AUD  Unveiling Q1 2021  IND filing mid-year 2021 • Collaborative pipeline – additional clinical entries • GalXC-Plus: CNS and other non-liver candidates